S-T Archives | Report Store | Pharma intelligence

show blocks helper

Sort by Default Order
- Default Order
- Name
- Price
- Date
- Popularity

Click to order products descending

Display 15 Products per page

Travivo

$10,000.00

Travivo (gepirone ER; GlaxoSmithKline/Mission Pharmacal) is a pyridinyl piperazine 5-HT1A receptor agonist, and is distinct from available therapies as it is not a reuptake inhibitor and has no material norepinephrine or dopamine activity. Unlike tricyclic antidepressants or selective serotonin reuptake inhibitors that act on most or all of the 5-HT subtypes in the brain and may have several adverse effects, trials for Travivo have shown benign adverse effects without significant dopaminergic effects.
March 29, 2019
Find out more
SAGE-217

$10,000.00

SAGE-217 (oral brexanolone; SAGE Therapeutics/Shionogi) is a novel, next-generation positive allosteric modulator that selectively binds synaptic and extrasynaptic gamma-aminobutyric acid-A (GABA-A) receptors and shares similar pharmacology properties to brexanolone.
March 29, 2019
Find out more
Trintellix

$10,000.00

Trintellix (vortioxetine; Lundbeck/Takeda) is the latest antidepressant to be approved in the US for major depressive disorder (MDD). The drug follows a successful line of antidepressants developed by Lundbeck, which includes Cipralex (escitalopram) and Cipramil (citalopram). Trintellix was first approved in the US in September 2013 and was made commercially available in January 2014, under the brand name Brintellix.
March 29, 2019
Find out more
Seroquel/Seroquel XR

$10,000.00

The Seroquel franchise contains quetiapine, which acts as an antagonist at multiple neurotransmitter receptors in the brain, such as serotonin 5-HT1A and 5-HT2, dopamine D1 and D2, histamine H1, and adrenergic alpha 1 and alpha 2 receptors.
March 29, 2019
Find out more
Tecentriq

$10,000.00

Tecentriq (atezolizumab; Roche/Chugai) is an antibody designed to target programmed death-ligand 1 (PD-L1) on tumor cells, allowing the body’s immune system to recognize and properly respond to the tumor.
March 6, 2019
Find out more
Sutent

$10,000.00

Sutent (sunitinib; Pfizer) is an orally available multi-targeted tyrosine kinase inhibitor which specifically inhibits vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), c-KIT, and FLT3.
March 6, 2019
Find out more
Torisel

$10,000.00

Torisel (temsirolimus; Pfizer) is an inhibitor of mammalian target of rapamycin (mTOR), which is an intracellular protein that has been implicated in multiple growth-related cellular functions.
March 6, 2019
Find out more
Treanda/Bendeka

$10,000.00

Treanda (bendamustine; Teva/Mundipharma/Eisai) is an intravenous cytotoxic agent.
January 31, 2019
Find out more
Synflorix

$10,000.00

Synflorix (GlaxoSmithKline/Japan Vaccine) is a 10-valent pneumococcal conjugate vaccine active against Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.
December 21, 2018
Find out more
Tyvaso

$10,000.00

United Therapeutics developed Tyvaso (treprostinil) as a follow-on product to Remodulin. As an inhaled formulation of treprostinil
October 29, 2018
Find out more
Tracleer

$10,000.00

Actelion’s Tracleer (bosentan) was the first oral therapy to be developed specifically for the treatment of pulmonary arterial hypertension (PAH).
October 29, 2018
Find out more
Selinexor

$10,000.00

Selinexor (Karyopharm/NPM Pharma) selectively inhibits the transport protein exportin-1 (XPO1), also called chromosome region maintenance-1.
October 9, 2018
Find out more
Synagis

$10,000.00

Synagis (palivizumab; AstraZeneca/AbbVie) is the global standard of care for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in children at high risk of RSV disease.
October 5, 2018
Find out more
Symdeko

$10,000.00

Vertex’s Symdeko ([tezacaftor + ivacaftor]) is a cystic fibrosis transmembrane conductance regulator (CFTR) corrector compound
September 3, 2018
Find out more
Tobi/Tobi Podhaler

$10,000.00

Tobi and the next-generation Tobi Podhaler are the gold-standard inhaled antibiotic treatments for cystic fibrosis patients.
September 3, 2018
Find out more

S-T

S-T

Travivo

SAGE-217

Trintellix

Seroquel/Seroquel XR

Tecentriq

Sutent

Torisel

Treanda/Bendeka

Synflorix

Tyvaso

Tracleer

Selinexor

Synagis

Symdeko

Tobi/Tobi Podhaler